Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Waking Beta Cells
NCT03632759Phase 1Completed
- Start
- Aug 2018
- Primary completion
- Nov 2021
- Modality
- Peptides, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of liraglutide and golimumab in type 1 diabetes mellitus (T1D) (2 arms). Primary endpoint: Proportion of individuals with peak MMTT stimulated C-peptide >0.017 pmol/mL at 8 weeks. Started Aug 2018; status: completed.
02
Drugs
liraglutidegolimumab
03
Conditions
type 1 diabetes mellitus (T1D)
Beyond the preview
Go deeper on NCT03632759.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03632759.